Mesoglycan in peripheral obstructive arterial disease (POAD). Clinical studies.
|Author||Study design||Pathology||Patients ()||Doses/route||Results|
|Andreozzi ||Prospective||POAD in stages I-II Fontaine||10||Mesoglycan 60 mg daily|
for 20 days
|Mesoglycan: safe and effective in improving the wall response to vasodilator stimulus|
|Raso ||Prospective||POAD stage IIb Fontaine||36||Mesoglycan 60 mg daily endovenous for 10 days then 100 mg daily orally for 20 days, repeated for two months then oral mesoglycan for 12 months||Mesoglycan: significant improvement of symptoms and signs in all patients but one|
|Nenci ||Randomized, double-blinded||PAOD stage II Fontaine||242||Mesoglycan 30 mg daily i.m. for 3 weeks then 100 mg daily orally for two weeks, versus matching placebo All patients receive ASA||Mesoglycan: significant clinical improvement versus placebo. Significant improvement in quality of life scores.|